Total Payments
$47,017
2022 Payments
$49.44
Companies
17
Transactions
140
Medicare Patients
2,190
Medicare Billing
$177,552
Payment Breakdown by Category
Other$36,146 (76.9%)
Research$5,145 (10.9%)
Food & Beverage$3,152 (6.7%)
Travel$1,339 (2.8%)
Consulting$1,200 (2.6%)
Education$34.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,875 | 36 | 52.9% |
| Honoraria | $11,271 | 4 | 24.0% |
| Unspecified | $5,145 | 3 | 10.9% |
| Food and Beverage | $3,152 | 86 | 6.7% |
| Travel and Lodging | $1,339 | 9 | 2.8% |
| Consulting Fee | $1,200 | 1 | 2.6% |
| Education | $34.95 | 1 | 0.1% |
Payments by Type
General
$41,872
137 transactions
Research
$5,145
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $25,297 | 56 | $0 (2021) |
| Aqua Pharmaceuticals | $15,064 | 20 | $0 (2017) |
| Eli Lilly and Company | $5,145 | 3 | $0 (2018) |
| PFIZER INC. | $574.73 | 27 | $0 (2020) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $282.94 | 9 | $0 (2020) |
| Journey Medical Corporation | $274.14 | 6 | $0 (2019) |
| Almirall LLC | $124.64 | 5 | $0 (2019) |
| Gilead Sciences, Inc. | $77.96 | 3 | $0 (2022) |
| TARO PHARMACEUTICALS USA, INC. | $30.67 | 2 | $0 (2019) |
| Mission Pharmacal Company | $25.91 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $49.44 | 2 | Gilead Sciences, Inc. ($33.41) |
| 2021 | $60.85 | 3 | Gilead Sciences, Inc. ($44.55) |
| 2020 | $79.31 | 5 | Ortho Dermatologics, a division of Bausch Health US, LLC ($37.95) |
| 2019 | $2,585 | 44 | Galderma Laboratories, L.P. ($1,526) |
| 2018 | $13,326 | 34 | Galderma Laboratories, L.P. ($12,187) |
| 2017 | $30,917 | 52 | Aqua Pharmaceuticals ($15,064) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/17/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $33.41 | General |
| Category: ONC | ||||||
| 02/11/2022 | Sun Pharmaceutical Industries Inc. | Winlevi (Drug), Absorica LD | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Dermatology | ||||||
| 11/23/2021 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: ACNE | ||||||
| 09/20/2021 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: ONC | ||||||
| 04/13/2021 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: ONC | ||||||
| 03/18/2020 | Ortho Dermatologics, a division of Bausch Health US, LLC | DUOBRII (Drug) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: DERMATOLOGY | ||||||
| 03/11/2020 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: DERMATOLOGY | ||||||
| 02/14/2020 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: ACNE | ||||||
| 02/12/2020 | Ortho Dermatologics, a division of Bausch Health US, LLC | DUOBRII (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: DERMATOLOGY | ||||||
| 01/27/2020 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: DERMATOLOGY | ||||||
| 12/20/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: DERMATOLOGY | ||||||
| 11/13/2019 | Almirall LLC | Veltin (Drug) | Food and Beverage | Cash or cash equivalent | $16.04 | General |
| Category: Dermatology | ||||||
| 11/11/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $10.05 | General |
| Category: DERMATOLOGY | ||||||
| 11/04/2019 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: ACNE | ||||||
| 10/15/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: DERMATOLOGY | ||||||
| 10/09/2019 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: ROSACEA | ||||||
| 10/03/2019 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Dermatology | ||||||
| 09/19/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: DERMATOLOGY | ||||||
| 09/18/2019 | Ortho Dermatologics, a division of Bausch Health US, LLC | DUOBRII (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: DERMATOLOGY | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | SIVEXTRO (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/06/2019 | Galderma Laboratories, L.P. | SOOLANTRA (Drug) | Food and Beverage | In-kind items and services | $148.77 | General |
| Category: ROSACEA | ||||||
| 09/03/2019 | Ortho Dermatologics, a division of Bausch Health US, LLC | DUOBRII (Drug) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: DERMATOLOGY | ||||||
| 09/03/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $6.03 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $2,316 | 1 |
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $1,927 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $902.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 654 | 1,351 | $157,678 | $54,985 |
| 2022 | 10 | 552 | 1,061 | $135,823 | $48,047 |
| 2021 | 10 | 541 | 1,053 | $128,187 | $44,888 |
| 2020 | 9 | 443 | 789 | $112,642 | $29,631 |
Total Patients
2,190
Total Services
4,254
Medicare Billing
$177,552
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 212 | 300 | $58,046 | $21,159 | 36.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 135 | 169 | $37,885 | $13,037 | 34.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 93 | 146 | $21,440 | $6,548 | 30.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 64 | 562 | $8,281 | $3,158 | 38.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 35 | 35 | $8,407 | $2,717 | 32.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 26 | $7,102 | $2,364 | 33.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 37 | 42 | $5,115 | $1,763 | 34.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 26 | 41 | $4,536 | $1,695 | 37.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,913 | $1,507 | 38.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $2,954 | $1,039 | 35.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 178 | 235 | $46,276 | $16,450 | 35.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 98 | 122 | $28,155 | $10,144 | 36.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 64 | 109 | $16,276 | $5,130 | 31.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 43 | 43 | $10,450 | $3,611 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 36 | $9,986 | $3,537 | 35.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 33 | 59 | $6,766 | $2,526 | 37.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 48 | 397 | $6,034 | $2,336 | 38.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $5,775 | $2,064 | 35.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 19 | 19 | $3,019 | $1,128 | 37.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 24 | 25 | $3,085 | $1,119 | 36.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 148 | 177 | $34,693 | $13,027 | 37.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 106 | 133 | $31,529 | $11,048 | 35.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 66 | 101 | $15,629 | $4,560 | 29.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 44 | $12,328 | $4,550 | 36.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 42 | 42 | $10,116 | $3,577 | 35.4% |
About Dr. Mark Goldstein, MD
Dr. Mark Goldstein, MD is a Dermatology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1902947484.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Goldstein, MD has received a total of $47,017 in payments from pharmaceutical and medical device companies, with $49.44 received in 2022. These payments were reported across 140 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($24,875).
As a Medicare-enrolled provider, Goldstein has provided services to 2,190 Medicare beneficiaries, totaling 4,254 services with total Medicare billing of $177,552. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location New Haven, CT
- Active Since 02/09/2007
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1902947484
Products in Payments
- EPIDUO FORTE (Drug) $13,408
- ORACEA (Drug) $7,832
- SOOLANTRA (Drug) $3,129
- Altabax (Drug) $2,262
- Acticlate (Drug) $1,522
- MIRVASO (Drug) $900.00
- EUCRISA (Drug) $574.73
- DUOBRII (Drug) $214.42
- Exelderm (Drug) $203.32
- Trodelvy (Drug) $77.96
- Ceracade (Drug) $70.82
- Veltin (Drug) $51.08
- BRYHALI (Drug) $39.11
- AKLIEF (Drug) $28.33
- Avar (Drug) $25.91
- Alcortin A (Drug) $23.52
- Seysara (Drug) $23.01
- SIVEXTRO (Drug) $17.70
- EFUDEX (Drug) $17.34
- NAFTIN (Drug) $17.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New Haven
Dr. Keith Choate, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $672,063
Dermatology $672,063
David Leffell, Md, MD
Dermatology — Payments: $173,525
Dermatology $173,525
Richard Antaya, Md, MD
Dermatology — Payments: $73,754
Dermatology $73,754
Dr. Lisa Donofrio, M.d, M.D
Dermatology — Payments: $59,053
Dermatology $59,053
Dr. Jonathan Leventhal, M.d, M.D
Dermatology — Payments: $58,910
Dermatology $58,910
Peter Heald, Md, MD
Dermatology — Payments: $50,990
Dermatology $50,990